MFM-223

Androgen receptor studies, study of mammary carcinoma

Human caucasian mammary carcinoma

STR-PCR Data: Amelogenin: X
CSF1PO: 10
D13S317: 8,12
D16S539: 11
D5S818: 11,12
D7S820: 8,10
THO1: 6,9.3
TPOX: 8
vWA: 17

The mammary carcinoma cell line MFM-223 was obtained from the pleural effusion of a postmenopausal breast cancer patient. The patient had not received any prior treatment and the tumour was classified as a widespread ductal mammary carcinoma with the histological grade of III. The cell line is characterised by high androgen, (approximately 100,000 binding sites per cell) and low oestrogen and progesterone receptor levels. Proliferation of cells was inhibited by addition of the androgen dihydrotestosterone at concentrations above 0.01 nM. MFM-223 have a characteristic pattern of isoenzyme polymorphism and of karyotype alterations revealing marker chromosomes and homogenously staining regions. Most cells have been near diploid with 10% displaying near tetraploidy. The cells have been tested to be free of Hepatitis B and C viruses and HIV. MFM-223 is tumourigenic in nude mice.

MEM + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).

Split sub-confluent cultures (70-80%) 1:3 using 0.25% trypsin or trypsin/EDTA; 5% CO₂; 37°C.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.